Regeneron Expands Bispecifics, Gene Therapy Programs As Exec Hints At More Deals

The drug maker reported what it said were encouraging early uptake signs for Eylea HD while also seeking to reassure analysts concerned about its BCMA-directed bispecific’s differentiation.

• Source: Shutterstock

Despite concerns about increasing competition, Regeneron Pharmaceuticals, Inc. is expanding its footprints in bispecific antibodies and in gene therapy – and management indicated the firm may be on the lookout for additional development deals.

The Tarrytown, NY-based drug maker announced its third quarter earnings on 2 November, reporting that sales increased 15% year-over-year to $3

Key Takeaways
  • Regeneron announced its third quarter 2023 earnings, with sales up 15% year-over-year.

  • The original version of Eylea posted declining sales, but the company pointed to hopeful signs for the newly approved high-dose version

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By 

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By 

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.